Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:CADLNASDAQ:LIMNNASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.66+0.5%$0.65$0.51▼$1.80$62.54M0.29561,332 shs200,119 shsCADLCandel Therapeutics$4.99-2.2%$5.23$3.79▼$14.60$255.53M-0.911.47 million shs548,558 shsLIMNLiminatus Pharma$6.93-23.2%$0.00$4.40▼$33.66$234.66MN/A438,335 shs218,015 shsPVLAPalvella Therapeutics$24.90+3.2%$23.30$6.20▼$29.27$266.66M-0.11130,255 shs64,899 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-3.63%+2.35%-0.83%+22.88%-54.42%CADLCandel Therapeutics-2.16%-1.38%-17.38%+13.67%-14.26%LIMNLiminatus Pharma-23.17%-37.85%+692,999,900.00%+692,999,900.00%+692,999,900.00%PVLAPalvella Therapeutics+3.23%+10.47%-1.97%+21.40%+2,489,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio1.6217 of 5 stars3.50.00.00.01.10.81.3CADLCandel Therapeutics2.4727 of 5 stars3.51.00.00.03.31.70.6LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/APVLAPalvella Therapeutics3.3569 of 5 stars3.60.00.00.02.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75319.02% UpsideCADLCandel Therapeutics 3.00Buy$22.00340.88% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/APVLAPalvella Therapeutics 3.13Buy$46.2985.89% UpsideCurrent Analyst Ratings BreakdownLatest ASRT, LIMN, CADL, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.005/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.005/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.50$0.05 per share13.30$1.27 per share0.52CADLCandel TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AN/APVLAPalvella Therapeutics$42.81M6.43N/AN/A$5.58 per share4.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.32N/A21.88N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/APVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)Latest ASRT, LIMN, CADL, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.361.661.35CADLCandel Therapeutics0.014.644.64LIMNLiminatus PharmaN/AN/AN/APVLAPalvella TherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CADLCandel Therapeutics13.93%LIMNLiminatus PharmaN/APVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%CADLCandel Therapeutics16.60%LIMNLiminatus PharmaN/APVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.78 million91.95 millionOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableLIMNLiminatus PharmaN/A26.02 millionN/AN/APVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/AASRT, LIMN, CADL, and PVLA HeadlinesRecent News About These CompaniesPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $46.29 Average PT from AnalystsJuly 6 at 2:09 AM | americanbankingnews.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJuly 3, 2025 | marketbeat.comPalvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025June 30, 2025 | quiverquant.comQPalvella Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.comStrid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)June 29, 2025 | marketbeat.comPVLA - Palvella Therapeutics Inc Key Metrics - MorningstarJune 27, 2025 | morningstar.comMPVLA - Palvella Therapeutics Inc Executives - MorningstarJune 26, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...June 24, 2025 | manilatimes.netMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - MorningstarJune 24, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - NasdaqJune 24, 2025 | nasdaq.comPalvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN RapamycinJune 24, 2025 | msn.comPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026June 23, 2025 | quiverquant.comQPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%June 23, 2025 | globenewswire.comPalvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR InhibitorsJune 18, 2025 | globenewswire.comPalvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN RapamycinJune 13, 2025 | msn.comCantor Fitzgerald Comments on PVLA FY2026 EarningsJune 11, 2025 | marketbeat.comPalvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic MalformationsJune 9, 2025 | quiverquant.comQPalvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsJune 9, 2025 | globenewswire.comCitadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)June 9, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJune 8, 2025 | marketbeat.comPalvella Therapeutics Advances in Rare Skin Disease TherapiesMay 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASRT, LIMN, CADL, and PVLA Company DescriptionsAssertio NASDAQ:ASRT$0.66 +0.00 (+0.51%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.66 +0.00 (+0.56%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Candel Therapeutics NASDAQ:CADL$4.99 -0.11 (-2.16%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$5.00 +0.01 (+0.20%) As of 07/7/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Liminatus Pharma NASDAQ:LIMN$6.93 -2.09 (-23.17%) As of 07/7/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Palvella Therapeutics NASDAQ:PVLA$24.90 +0.78 (+3.23%) As of 07/7/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
